Nanjing Leads Biolabs Co.,ltd

This study tests a new drug (LBL-024) combined with a standard chemotherapy (paclitaxel) in people with ovarian cancer that no longer responds to platinum-based treatments. About 110 adults will receive the combination to see if it shrinks tumors and how safe it is. The goal is t…

This study tests a new drug called LBL-024 combined with other medicines in about 110 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the combination can shrink tumors or stop them from growing. Participants will receiv…

This study is testing a new drug called LBL-024 combined with standard chemotherapy (etoposide and platinum) as a first treatment for people with advanced neuroendocrine carcinoma (NEC), a rare and aggressive cancer. About 178 adults aged 18-75 will take part. The goal is to see …

This study tests a new drug called LBL-024 combined with other medicines in 140 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the combination can shrink tumors or stop them from growing. Participants will receive the …

This study tests an experimental drug called LBL-034 in people whose multiple myeloma has returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 342 adults will take part in this early-phase trial ac…

This study tests a new drug called LBL-024 combined with other medicines in 110 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the combination can shrink tumors (objective response rate). Participants must be 18 or old…

This early-stage study tests a single injection of a new drug, LBL-047, in healthy adults and people with mild-to-moderate systemic lupus erythematosus (lupus). The main goal is to check for side effects and how the drug moves through the body. About 112 participants will receive…

This study is testing a new drug called LBL-024, either alone or combined with other treatments (LBL-007 or toripalimab), in people with advanced melanoma that has spread. The goal is to see if these combinations can shrink tumors or slow the disease. About 200 adults will take p…

This study tests an experimental drug called LBL-024, given alone or with chemotherapy, in people whose triple negative breast cancer has come back or spread. The goal is to see if the drug can shrink tumors and slow the disease. About 220 adults with this aggressive cancer type …

This study tests a new drug called LBL-024 combined with other medicines in 230 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the combination can shrink tumors (objective response rate). Participants will receive the …